Key facts
- This page summarizes Sabeen Mekan's Form 3 filing for Zymeworks Inc. (ZYME).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 02 Feb 2026, 20:37.
Sabeen Mekan - 01 Feb 2026 Form 3 Insider Report for Zymeworks Inc. (ZYME)
- Reporting relationship
- SVP & Chief Medical Officer
- Issuer ticker
- ZYME
- Reported as of
- 01 Feb 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Catherine Graham, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Sabeen Mekan filed Form 3 for Zymeworks Inc. (ZYME) on 02 Feb 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002106866
Primary reporting owner
Mekan Sabeen
- Relationship
- SVP & Chief Medical Officer
- Address
- C/O ZYMEWORKS INC., 108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
- Signature
- /s/ Catherine Graham, Attorney-in-Fact
- Signature date
- 02 Feb 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZYME
holding
No securities are beneficially owned
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 01 Feb 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZYME
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 192,000
- Exercise price
- $11.75
- Footnotes
- F1, F2
ZYME
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 29,000
- Exercise price
- $23.16
- Footnotes
- F2, F3
ZYME
holding
Derivative
Restricted Stock Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,000
- Exercise price
- Footnotes
- F4, F5
ZYME
holding
Derivative
Performance Stock Unit
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,000
- Exercise price
- Footnotes
- F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 7 footnotes
Footnote F1
Stock option granted April 21, 2025.
Footnote F2
Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
Footnote F3
Stock option granted January 12, 2026.
Footnote F4
Restricted stock units ("RSUs") granted January 12, 2026. RSUs vest in four equal annual installments beginning on first anniversary of grant date.
Footnote F5
Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
Footnote F6
Performance restricted stock units ("PSUs") granted January 12, 2026. Each PSU represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 16,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.
Footnote F7
(Continued from footnote 6) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney